Free circulating mRNA in plasma from breast cancer patients and clinical outcome.
We studied by real-time PCR cyclin D1 and thymidylate synthase (TS) mRNA in plasma as possible markers of clinical outcome in breast cancer. We observed poor outcome in patients with presence of cyclin D1 mRNA in good-prognosis groups, such as negative vascular invasion. Presence of both markers was associated with non-response to treatment after relapse. In patients treated with tamoxifen, a trend to significant relation between poor outcome and cyclin D1 mRNA was found. Cyclin D1 mRNA in plasma could identify patients with poor overall survival in good-prognosis groups and patients non-responsive to tamoxifen.
García
Vanesa
V
Department of Medical Oncology, Hospital Universitario Puerta de Hierro, C/ San Martín de Porres, 4, E-28035 Madrid, Spain.
García
José M
JM
Peña
Cristina
C
Silva
Javier
J
Domínguez
Gemma
G
Lorenzo
Yolanda
Y
Diaz
Raquel
R
Espinosa
Pablo
P
de Sola
Javier García
JG
Cantos
Blanca
B
Bonilla
Félix
F
D001943:Breast Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000401:mortality; D019938:Cyclin D1 / Q000032:analysis* / Q000097:blood; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D011379:Prognosis; D011446:Prospective Studies; D012333:RNA, Messenger / Q000097:blood*; D016019:Survival Analysis; D013629:Tamoxifen / Q000627:therapeutic use; D013940:Thymidylate Synthase / Q000097:blood / Q000235:genetics*; D016896:Treatment Outcome
D012333:RNA, Messenger; D013629:Tamoxifen; D019938:Cyclin D1; D013940:Thymidylate Synthase